SAB Biotherapeutics, Inc. (SABS)
NASDAQ: SABS · Real-Time Price · USD
3.410
-0.050 (-1.45%)
Sep 15, 2026, 4:00 PM EDT - Market closed
SAB Biotherapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| - | - | 1.32 | 2.24 | 23.9 | 60.88 | |
Revenue Growth | - | - | -40.94% | -90.63% | -60.73% | 10.21% |
Cost of Revenue | 48.27 | 33.35 | 29.55 | 16.52 | 36.44 | 57.18 |
Gross Profit | -48.27 | -33.35 | -28.23 | -14.28 | -12.53 | 3.69 |
Selling, General & Admin | 23.56 | 15.6 | 14.68 | 23.8 | 16.38 | 17.09 |
Operating Expenses | 23.56 | 15.6 | 14.68 | 23.8 | 16.38 | 17.09 |
Operating Income | -71.82 | -48.95 | -42.91 | -38.08 | -28.92 | -13.39 |
Interest Expense | -0.23 | -0.24 | -0.32 | -0.32 | -0.3 | -0.29 |
Interest & Investment Income | 4.11 | 1.43 | 1.29 | 0.58 | 0.07 | 0.02 |
Other Non Operating Income (Expenses) | 55.17 | 61.04 | 7.84 | -4.39 | 10.38 | -4.15 |
EBT Excluding Unusual Items | -12.78 | 13.27 | -34.11 | -42.19 | -18.76 | -17.81 |
Gain (Loss) on Sale of Assets | - | - | - | - | 0.02 | - |
Other Unusual Items | - | - | - | - | 0.03 | 0.67 |
Pretax Income | -12.78 | 13.27 | -34.11 | -42.19 | -18.72 | -17.14 |
Income Tax Expense | - | - | - | - | 0.03 | - |
Net Income | -12.78 | 13.27 | -34.11 | -42.19 | -18.74 | -17.14 |
Preferred Dividends & Other Adjustments | 9.01 | 9.01 | - | - | - | - |
Net Income to Common | -21.79 | 4.26 | -34.11 | -42.19 | -18.74 | -17.14 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 48 | 19 | 9 | 6 | 4 | 3 |
Shares Outstanding (Diluted) | 48 | 61 | 9 | 6 | 4 | 3 |
Shares Change | 417.54% | 562.28% | 67.74% | 26.86% | 59.20% | 1.21% |
EPS (Basic) | -0.45 | 0.22 | -3.68 | -7.64 | -4.31 | -6.27 |
EPS (Diluted) | -1.56 | -0.79 | -3.68 | -7.64 | -4.31 | -6.30 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -57.44 | -45.71 | -34.63 | -25.32 | -25.63 | -8.96 |
Free Cash Flow Per Share | -1.20 | -0.74 | -3.74 | -4.58 | -5.89 | -3.28 |
Gross Margin | - | - | - | - | -52.44% | 6.07% |
Operating Margin | - | - | -3244.87% | -1700.56% | -120.97% | -22.00% |
Profit Margin | - | - | -2579.03% | -1884.50% | -78.40% | -28.16% |
Free Cash Flow Margin | - | - | -2618.65% | -1130.71% | -107.20% | -14.71% |
EBITDA | -68.71 | -45.87 | -38.12 | -34.33 | -25.63 | -11.9 |
EBITDA Margin | - | - | - | - | -107.20% | -19.55% |
D&A For EBITDA | 3.12 | 3.08 | 4.79 | 3.75 | 3.29 | 1.49 |
EBIT | -71.82 | -48.95 | -42.91 | -38.08 | -28.92 | -13.39 |
EBIT Margin | - | - | - | - | -120.97% | -22.00% |
Revenue as Reported | - | - | 1.32 | 2.24 | 23.9 | 60.88 |